Supraventricular tachycardias (SVTs) are rapid rhythm disturbances originating from the atria or the atrioventricular (AV) node. In the absence of a bundle branch block, there is intact conduction to the ventricles via the right and left bundles leading to a narrow and normal-appearing QRS. Therefore, these arrhythmias are also often called narrow complex tachycardias. Because many of the SVTs are episodic, many clinicians also refer to this group of arrhythmias as paroxysmal SVTs. Radiofrequency ablation has become an important therapeutic option in the management of SVTs because of its ability to cure these arrhythmias safely. Table 11–1 outlines the pharmacologic therapy for SVTs.
Table 11–1. Antiarrhythmic Drugs for Supraventricular Tachycardias
| Agent | Indication | Intravenous Dose | Oral Dose | Adverse Effects | Drug Interactions |
|---|---|---|---|---|---|
| Class Ia | |||||
| Quinidine | AF, AFL, AVNRT, AVRT | 6–10 mg/kg over 20–30 min | 200–400 mg q4–6h; q8h with long-acting preparations | Hypotension (especially IV), ventricular proarrhythmia, GI disturbance, thrombocytopenia | ↑Digitalis level ↑Warfarin effect ↑Metoprolol, propranolol, propafenone levels |
| Procainamide | AF, AFL, AVNRT, AVRT | Bolus: 15 mg/kg given as 20 mg/min Infusion: 2–4 mg/min | 50 mg/kg/day q3–4h; twice daily dosage with longacting preparation | GI disturbance, hypotension, SLE, agranulocytosis, FUO hemolytic anemia, myasthenia gravis aggravation, ventricular proarrhythmia | ↑Procainamide level with cimetidine, quinidine, and amiodarone |
| Class Ic | |||||
| Flecainide | AF, AFL, AT, AVNRT, AVRT | N/A | 50–200 mg q12h | Ventricular proarrhythmia, CHF, GI disturbance, CNS (dizziness, tremor, light-headedness) | ↑Digitalis level ↑Flecainide level with amiodarone, cimetidine, Norpace, propranolol ↓Flecainide level with smoking |
| Propafenone | AF, AFL, AVNRT, AVRT | N/A | 150–300 mg q8h or 225–425 mg bid (long-acting form) | GI disturbance, CNS (dizziness), metallic taste, CHF, first-degree AVB, IVCD, positive ANA | Synergism with β-blockers |
| Class II (IV) | |||||
| Esmolol | Ventricular rate control for AF, AFL, ST, AT | Bolus: 500 mcg/kg over 1–2 min Infusion: 50–200 mcg/kg/min | N/A | CHF, AVB, bradycardia, bronchospasm | |
| Propranolol | Ventricular rate control for AF, AFL, ST, AT | 1–5 mg at 1 mg/min | 20–320 mg/day q6h, q8h, q12h, or once daily, depending on preparation | CHF, AVB, bradycardia, bronchospasm | |
| Class III | |||||
| Sotalol | AF, AFL, AVNRT, AVRT, AT | N/A | 80–160 mg q12h | Dyspnea, fatigue, dizziness, CHF, bradycardia, ventricular proarrhythmia, bronchospasm | Synergism with Ca2+ antagonists or β-blockers |
| Amiodarone | AF, AFL, AVNRT, AVRT, AT | Bolus: 150 mg over 10 min Infusion: 1 mg/min × 6 h, then 0.5 mg/min | 100–400 mg once daily | Pulmonary toxicity, CHF, tremor, bradycardia, ↑ LFTs, corneal deposits, skin discoloration, GI intolerance, hyper-/hypothyroidism | ↑Digoxin levels ↑Warfarin effect ↑Quinidine, procainamide/NAPA, flecainide ↑Phenytoin level |
| Ibutilide | AF, AFL | 1 mg bolus over 10 min; second bolus, if needed, after 10-min wait | N/A | Ventricular proarrhythmia, hypotension, GI disturbance | |
| Dofetilide | AF, AFL | N/A | 125–500 mcg twice daily modified by algorithm | Ventricular proarrhythmia, headache, chest pain, nausea, dizziness | Contraindicated with verapamil, cimetidine, ketoconazole, trimethoprim |
| Class IV | |||||
| Diltiazem | AF, AFL, AVNRT, AVRT, AT, MAT | Bolus: 0.25 mg/min over 2 min then 0.35 mg/kg in 15 min if needed Infusion: 5–15 mg/h | 90–360 mg/day in 1–4 divided doses, depending on preparation | Hypotension, bradycardia, CHF, AVB | Synergism with β-blockers |
| Verapamil | AF, AFL, AVNRT, AVRT, AT, MAT | 2.5–20 mg over 20 min in divided doses | 40–120 mg q8h; 240–360 mg once daily of longacting preparation | Hypotension, bradycardia, CHF, AVB | Synergism with β-blockers |
| Class V | |||||
| Adenosine | SVT diagnosis, AVNRT, AVRT, AT termination | 6 mg IV rapid bolus followed by 12 mg × 2 if needed; half dosage if administered in central line | N/A | Chest tightness, facial flushing, dyspnea, AVB | ↑Activity by dipyridamole ↓Activity by theophylline |
| Digoxin | Ventricular rate control for AF, AFL, AT (generally not very effective in active patients) | Up to 1.0 mg bolus in divided doses followed by 0.125–0.375 mg/day | 0.125–0.375 mg/day in single dose | GI disturbance, conduction defects, atrial/ventricular arrhythmias, headache, visual disturbances | ↑Digoxin level: amiodarone, quinidine, verapamil, indomethacin, spironolactone, alprazolam, erythromycin, tetracycline ↓Digoxin level: antacids, cholestyramine, rifampin, neomycin ↑Risk of digitalis toxicity with potassium-depleting diuretics |
AF, atrial fibrillation; AFL, atrial flutter; ANA, antinuclear antigen; AT, atrial tachycardia; AVB, atrioventricular block; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reciprocating tachycardia; CHF, congestive heart failure; CNS, central nervous system; FUO, fever of unknown origin; GI, gastrointestinal; IV, intravenous; IVCD, intraventricular conduction delay; LFT, liver function tests; MAT, multifocal atrial tachycardia; N/A, not applicable; NAPA, N-acetyl procainamide; SLE, systemic lupus erythematosus; ST, sinus tachycardia.
Tachyarrhythmias occur as a result of three main mechanisms: reentry, which is most common; enhanced or abnormal automaticity; and triggered activity.
Reentrant arrhythmias sustain themselves by repetitively following a revolving pathway comprising two limbs, one that takes the impulse away from and one that carries it back to the site of origin. For reentry to exist, an area of slow conduction must occur, and each limb must have a different refractory period (see the discussion on AV nodal reentrant tachycardia). In this situation, ectopic beats or pacing (by inducing refractoriness in one limb of the circuit) can initiate a reentrant tachycardia. Once established, ectopic beats or pacing can also terminate the tachycardia by interfering with impulse propagation in one of the limbs.
The second mechanism, automaticity, refers to spontaneous and, often, repetitive firing from a single focus, which may either be ectopic or may originate in the sinus node. This mechanism comprises two subcategories. Enhanced automaticity is defined as a focus that fires spontaneously and may originate in the sinus node, subsidiary pacemakers in the atrium including the Eustachian ridge, Bachmann bundle, coronary sinus and AV valves, the AV node, His-Purkinje system, and the ventricles. Abnormal automaticity is usually secondary to a disease process causing alterations in ionic flow that produces a less negative resting diastolic membrane potential. Threshold potential is therefore more easily attained, thereby increasing the probability of a sustained arrhythmia.
The third mechanism, triggered arrhythmias, depends on oscillations in the membrane potential that closely follow an action potential. In the absence of a new external electrical stimulus, these oscillations, or after-depolarizations, cause new action potentials to develop. Thus, each new action potential results from the previous action potential. These arrhythmias can be produced by early or late after-depolarization, depending on the timing of the first after-depolarization relative to the preceding action potential (the one that spawned the triggered activity). In early after-depolarizations, membrane repolarization is incomplete, which allows an action potential to be initiated by a subthreshold stimulus. This type is often associated with electrolyte disturbance and may be the mechanism responsible for arrhythmogenesis related to the prolonged QT syndrome and torsades de pointes caused by quinidine. With delayed after-depolarization, membrane repolarization is complete, but an abnormal intracellular calcium load causes spontaneous depolarization. The high calcium levels can be related to the inhibition of the sodium pump by drugs such as digoxin. In either type of arrhythmia, the process may be repetitive and lead to a sustained tachycardia.
General Diagnostic ApproachA systematic approach to interpreting the 12-lead electrocardiogram (ECG) will allow accurate determination of the type of SVT in most cases (Figure 11–1). The first step is to determine whether the rhythm is regular or irregular. If it is irregular, the rhythm is likely either atrial fibrillation, atrial flutter with variable conduction, or multifocal atrial tachycardia (MAT). The appearance of the P waves or lack of P waves will usually distinguish between these three entities. In atrial fibrillation, there is chaotic atrial activity. In atrial flutter, P waves are seen at a rate of 240–320 bpm. In MAT, there are P waves preceding each QRS complex, and there are at least three different P-wave morphologies.
Figure 11-1. Algorithm for distinguishing supraventricular tachycardias. AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; AVNRT, atrioventricular nodal reentrant tachycardia; AVRT, atrioventricular reciprocating tachycardia; JT, junctional tachycardia; MAT, multifocal atrial tachycardia; SN, sinus node; ST, sinus tachycardia; SVT, supraventricular tachycardia.

If the SVT is regular, there are several main types of SVT to consider. The SVT could be sinus tachycardia, sinus node reentry, atrial flutter, atrial tachycardia, AV nodal reentrant tachycardia (AVNRT), junctional tachycardia, or atrioventricular reciprocating tachycardia (AVRT). The type of regular SVT can be usually identified by examining four aspects of the 12-lead ECG: onset and termination, heart rate, P-wave morphology, and R-P relationship. Sinus tachycardia and junctional tachycardia typically have very gradual onset, whereas the other SVTs usually start and stop more suddenly. Rate can also be helpful since sinus tachycardia cannot typically go over 220 bpm minus age, and the heart rate in atrial flutter is often a multiple of 300. P-wave morphology can be helpful because retrograde P waves (negative in the inferior leads: II, III, and aVF) favor AVNRT and junctional tachycardia. Finally, R-P relationship refers to the distance from the R wave to the next P wave during tachycardia. If this distance is longer than the P-R interval, the SVT is termed long R-P, whereas if this distance is short, it is termed short R-P (Figure 11–2).
Figure 11-2. Short R-P refers to a regular supraventricular tachycardia (SVT) where the R-P interval is shorter than the P-R interval. Long R-P refers to a regular SVT where the R-P interval is longer than the P-R interval.
